ER+/HER2- breast cancer

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

ER+/HER2- breast cancer
Nov 20, 2024, 11:30 | Insight
Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment
Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…
Nov 3, 2024, 16:08 | Insight
Yakup Ergün: Benefit of systemic therapy in MINDACT patients with small ER+ HER2- Breast Cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared a post on X about a recent…
Jul 15, 2024, 12:03 | Insight
Aleix Prat: Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared a post…
Apr 25, 2024, 21:06 | Drugs
Piotr Wysocki: Datopotamab deruxtecan – another anti-TROP2 conjugate demonstrating activity in advanced ER+/HER2- and triple-negative breast cancer patients
Piotr Wysocki recently shared on LinkedIn: "Datopotamab deruxtecan – a novel anti-TROP2 conjugate demonstrates activity…
Mar 27, 2024, 10:07 | Insight
Piotr Wysocki: No benefit of continuing CDK4/6i beyond progression in advanced ER+/HER2- breast cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 14, 2024, 19:28 | Drugs
François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus
Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…
Feb 9, 2024, 17:30 | Blog
Chris Boshoff: The U.S. FDA has granted Fast Track designation for our investigational treatment for ER+/HER2- breast cancer
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, posted on LinkedIn: "I’m…
All: 7 Posts: 1 - 100
Special Coverage